

Ischemia Reperfusion Injury - Pipeline Review, H2 2020

<https://marketpublishers.com/r/I572AD1BAEDEN.html>

Date: July 2020

Pages: 197

Price: US\$ 2,000.00 (Single User License)

ID: I572AD1BAEDEN

Abstracts

Ischemia Reperfusion Injury - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2020, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and

features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 6, 33 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 1 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Ischemia Reperfusion Injury - Overview

Ischemia Reperfusion Injury - Therapeutics Development

Ischemia Reperfusion Injury - Therapeutics Assessment

Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development

Ischemia Reperfusion Injury - Drug Profiles

Ischemia Reperfusion Injury - Dormant Projects

Ischemia Reperfusion Injury - Discontinued Products

Ischemia Reperfusion Injury - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Ischemia Reperfusion Injury, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..2), H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Companies, H2 2020 (Contd..2), H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Ischemia Reperfusion Injury - Pipeline by Acelerox LLC, H2 2020

Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, H2 2020

Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp, H2 2020

Ischemia Reperfusion Injury - Pipeline by Apollo Therapeutics LLC, H2 2020

Ischemia Reperfusion Injury - Pipeline by Aptorum Group Ltd, H2 2020

Ischemia Reperfusion Injury - Pipeline by Argenx SE, H2 2020

Ischemia Reperfusion Injury - Pipeline by Axolo Pharma Inc, H2 2020

Ischemia Reperfusion Injury - Pipeline by Balmes Transplantation SAS, H2 2020

Ischemia Reperfusion Injury - Pipeline by Beijing Northland Biotech Co Ltd, H2 2020

Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, H2 2020

Ischemia Reperfusion Injury - Pipeline by Celdara Medical LLC, H2 2020

Ischemia Reperfusion Injury - Pipeline by Cellmid Ltd, H2 2020

Ischemia Reperfusion Injury - Pipeline by CFM Pharma Holding BV, H2 2020

Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H2 2020

Ischemia Reperfusion Injury - Pipeline by Cypralis Ltd, H2 2020

Ischemia Reperfusion Injury - Pipeline by Domainex Ltd, H2 2020

Ischemia Reperfusion Injury - Pipeline by EVAS Therapeutics LLC, H2 2020

Ischemia Reperfusion Injury - Pipeline by Everon Biosciences Inc, H2 2020

Ischemia Reperfusion Injury - Pipeline by Gero Discovery, H2 2020

Ischemia Reperfusion Injury - Pipeline by Gilead Sciences Inc, H2 2020

Ischemia Reperfusion Injury - Pipeline by Glucox Biotech AB, H2 2020
Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, H2 2020
Ischemia Reperfusion Injury - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2020
Ischemia Reperfusion Injury - Pipeline by LG Chem Ltd, H2 2020
Ischemia Reperfusion Injury - Pipeline by Limulus Therapeutics Pty Ltd, H2 2020
Ischemia Reperfusion Injury - Pipeline by Mallinckrodt Plc, H2 2020
Ischemia Reperfusion Injury - Pipeline by Neuroene Therapeutics LLC, H2 2020
Ischemia Reperfusion Injury - Pipeline by New B Innovation Ltd, H2 2020
Ischemia Reperfusion Injury - Pipeline by New Horizons Pharma Inc, H2 2020
Ischemia Reperfusion Injury - Pipeline by Nour Heart Therapeutics LLC, H2 2020
Ischemia Reperfusion Injury - Pipeline by NuNerve Pty Ltd, H2 2020
Ischemia Reperfusion Injury - Pipeline by Orion Corp, H2 2020
Ischemia Reperfusion Injury - Pipeline by Pfizer Inc, H2 2020
Ischemia Reperfusion Injury - Pipeline by Pharming Group NV, H2 2020
Ischemia Reperfusion Injury - Pipeline by Proteo Inc, H2 2020
Ischemia Reperfusion Injury - Pipeline by Radikal Therapeutics Inc, H2 2020
Ischemia Reperfusion Injury - Pipeline by Reata Pharmaceuticals Inc, H2 2020
Ischemia Reperfusion Injury - Pipeline by Revive Therapeutics Ltd, H2 2020
Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2020
Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Corp, H2 2020
Ischemia Reperfusion Injury - Pipeline by TheraSource LLC, H2 2020
Ischemia Reperfusion Injury - Pipeline by United Therapeutics Corp, H2 2020
Ischemia Reperfusion Injury - Pipeline by Young Therapeutics LLC, H2 2020
Ischemia Reperfusion Injury - Dormant Projects, H2 2020
Ischemia Reperfusion Injury - Dormant Projects, H2 2020 (Contd..1), H2 2020
Ischemia Reperfusion Injury - Dormant Projects, H2 2020 (Contd..2), H2 2020
Ischemia Reperfusion Injury - Dormant Projects, H2 2020 (Contd..3), H2 2020
Ischemia Reperfusion Injury - Dormant Projects, H2 2020 (Contd..4), H2 2020
Ischemia Reperfusion Injury - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Ischemia Reperfusion Injury, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Acelerox LLC
Amyndas Pharmaceuticals LLC
Angion Biomedica Corp
Apollo Therapeutics LLC
Aptorum Group Ltd
Argenx SE
Axolo Pharma Inc
Balmes Transplantation SAS
Beijing Northland Biotech Co Ltd
Bolder Biotechnology Inc
Celdara Medical LLC
Cellmid Ltd
CFM Pharma Holding BV
Corline Biomedical AB
Cypralis Ltd
Domainex Ltd
EVAS Therapeutics LLC
Everon Biosciences Inc
Gero Discovery
Gilead Sciences Inc
Glucox Biotech AB

Ischemix Inc
Lee's Pharmaceutical Holdings Ltd
LG Chem Ltd
Limulus Therapeutics Pty Ltd
Mallinckrodt Plc
Neuroene Therapeutics LLC
New B Innovation Ltd
New Horizons Pharma Inc
Nour Heart Therapeutics LLC
NuNerve Pty Ltd
Orion Corp
Pfizer Inc
Pharming Group NV
Proteo Inc
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
Revive Therapeutics Ltd
SBI Pharmaceuticals Co Ltd
Stealth BioTherapeutics Corp
TheraSource LLC
United Therapeutics Corp
Young Therapeutics LLC

I would like to order

Product name: Ischemia Reperfusion Injury - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/I572AD1BAEDEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I572AD1BAEDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970